ArticleThe Journal of antibiotics2026
Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of multidrug-resistant Acinetobacter baumannii has significantly limited available treatment options and highlights the need for effective combination therapies. Novel tetracycline derivatives such as eravacycline and omadacycline may represent promising alternatives against resistant A. baumannii isolates. This study aimed to evaluate the in vitro antibacterial activities of these agents and to investigate their potential synergistic interactions with selected antimicrobial agents. The antibacterial activities of eravacycline, omadacycline, ceftazidime, meropenem, tobramycin, ciprofloxacin, and colistin were determined against 50 clinical isolates using the broth microdilution method. Synergistic interactions between eravacycline or omadacycline and five antimicrobial agents were evaluated in 10 meropenem-resistant isolates (MIC ≥ 8 µg/mL) by the checkerboard assay. Eravacycline and omadacycline demonstrated low MIC values against the tested isolates. Synergistic interactions were frequently observed, particularly in combinations with ceftazidime, meropenem, and colistin. Eravacycline and omadacycline showed promising in vitro activity both alone and in combination with conventional antimicrobial agents. These findings suggest that further studies are needed to clarify their potential role in the treatment of resistant Acinetobacter baumannii infections.
Indexed as
Identifiers
42204275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.